Orforglipron
Also known as: Foundayo, LY3502970
The first oral GLP-1 pill that can be taken at any time of day without food or water restrictions. FDA-approved on April 1, 2026 as Foundayo for weight management. A major step forward for people who want GLP-1 benefits without injections.
How it works
Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist, which is why it survives stomach acid and works as a pill. Like injectable GLP-1 drugs, it activates GLP-1 receptors to reduce appetite, slow stomach emptying, and improve blood sugar control. The key difference is you take it by mouth once a day.
Common uses
- Chronic weight management (FDA-approved)
- Type 2 diabetes (trials ongoing)
- Potential uses being studied: sleep apnea, osteoarthritis, hypertension
Side effects
- Nausea (most common, usually during dose escalation)
- Vomiting
- Diarrhea
- Constipation
- Decreased appetite
- Similar GI side effect profile to injectable GLP-1 drugs
Key research
- ATTAIN-1 trial showed 12.4% weight loss (27.3 lbs average) at highest dose over 36 weeks
- ATTAIN-2 trial showed 10.5% weight loss (22.9 lbs) with 36 mg dose
- Three successful Phase 3 trials triggered global regulatory submissions
- FDA approved April 1, 2026 under National Priority Voucher Program
Safety notes
- Newly FDA-approved (April 2026). Long-term safety data still limited
- Same class-wide thyroid C-cell tumor warning as other GLP-1 drugs
- Should be used alongside reduced-calorie diet and increased physical activity
- Available through LillyDirect and retail pharmacies starting April 2026
Too many clinics, not enough clarity?
We don't sell peptides. Tell us your goals and we'll connect you with a vetted provider who can figure out what actually makes sense for you.
See what's right for youExplore other peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management. One of the most well-studied peptides available.
Tirzepatide
A dual GIP/GLP-1 receptor agonist that has shown even greater weight loss results than semaglutide in head-to-head trials.
BPC-157
A synthetic peptide derived from human gastric juice, studied primarily in animal models for its regenerative and anti-inflammatory properties. Not FDA-approved.
CJC-1295 / Ipamorelin
A commonly paired combination of growth hormone-releasing peptides used to stimulate natural GH production for anti-aging, body composition, and recovery.